Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jining Medical Univ. GSK-3β compound 3c
- Development stage
- Preclinical
- Lead developer
- Jining Medical College
01
Overview
Jining Medical Univ. GSK-3β compound 3c: sourced facts only. name: "Notably, compound 3c demonstrated the greatest GSK-3β inhibitory effect (IC50 = 0.66 ± 0.19 nM) and favorable targeting specificity for GSK-3." [PMID:41855636]; target: "Notably, compound 3c demonstrated the greatest GSK-3β inhibitory effect (IC50 = 0.66 ± 0.19 nM) and favorable targeting specificity for GSK-3." [PMID:41855636]; developer: "Medical Research Center, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong, China." [PMID:41855636]; stage: "Notably, 3c obviously enhanced the motility of AD zebrafish and preliminarily demonstrated low toxicity." [PMID:41855636]
02
Targets
GSK3 (Glycogen synthase kinase 3 beta)
Beyond the preview
Go deeper on Jining Medical Univ. GSK-3β compound 3c.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jining Medical Univ. GSK-3β compound 3c.